JHU-2545 Preferentially Shields Salivary Glands and Kidneys During PSMA-targeted Imaging

Overview

Journal Eur J Nucl Med Mol Imaging

Specialties Biophysics
Nuclear Medicine
Radiology

Date 2025 Jan 1

PMID 39743616

Authors

Michael T Nedelcovych

Ranjeet P Dash

Ying Wu

Eun Yong Choi

Rena S Lapidus

Pavel Majer

Andrej Jancarik

Diane Abou

Marie-France Penet

Anastasia Nikolopoulou

Alex Amor-Coarasa

John Babich

Daniel L Thorek

Rana Rais

Clemens Kratochwil

Barbara S Slusher

Affiliations

Soon will be listed here.

Abstract

Purpose: Prostate-specific membrane antigen (PSMA) radioligand therapy is a promising treatment for metastatic castration-resistant prostate cancer (mCRPC). Several beta or alpha particle-emitting radionuclide-conjugated small molecules have shown efficacy in late-stage mCRPC and one, [[177Lu]Lu]Lu-PSMA-617, is FDA approved. In addition to tumor upregulation, PSMA is also expressed in kidneys and salivary glands where specific uptake can cause dose-limiting xerostomia and potential for nephrotoxicity. The PSMA inhibitor 2-(phosphonomethyl)pentanedioic acid (2-PMPA) can prevent kidney uptake in mice, but also blocks tumor uptake, precluding its clinical utility. Preferential delivery of 2-PMPA to non-malignant tissues could improve the therapeutic window of PSMA radioligand therapy.

Methods: A tris(isopropoxycarbonyloxymethyl) (TrisPOC) prodrug of 2-PMPA, JHU-2545, was synthesized to enhance 2-PMPA delivery to non-malignant tissues. Mouse pharmacokinetic experiments were conducted to compare JHU-2545-mediated delivery of 2-PMPA to plasma, kidney, salivary glands, and C4-2 prostate tumor xenograft. Imaging studies were conducted in rats and mice to measure uptake of PSMA PET tracers in kidney, salivary glands, and prostate tumor xenografts with and without JHU-2545 pre-treatment.

Results: JHU-2545 resulted in approximately 3- and 53-fold greater exposure of 2-PMPA in rodent salivary glands (18.0 ± 0.97 h*nmol/g) and kidneys (359 ± 4.16 h*nmol/g) versus prostate tumor xenograft (6.79 ± 0.19 h*nmol/g). JHU-2545 also blocked rodent kidneys and salivary glands uptake of the PSMA PET tracers [68Ga]Ga-PSMA-11 and [18 F]F-DCFPyL by up to 85% with little effect on tumor.

Conclusions: JHU-2545 pre-treatment may enable greater cumulative administered doses of PSMA radioligand therapy, possibly improving safety and efficacy.

References

Fendler W, Rahbar K, Herrmann K, Kratochwil C, Eiber M . Lu-PSMA Radioligand Therapy for Prostate Cancer. J Nucl Med. 2017; 58(8):1196-1200. DOI: 10.2967/jnumed.117.191023. View

Kratochwil C, Bruchertseifer F, Rathke H, Hohenfellner M, Giesel F, Haberkorn U . Targeted α-Therapy of Metastatic Castration-Resistant Prostate Cancer with Ac-PSMA-617: Swimmer-Plot Analysis Suggests Efficacy Regarding Duration of Tumor Control. J Nucl Med. 2018; 59(5):795-802. DOI: 10.2967/jnumed.117.203539. View

Sartor O, de Bono J, Chi K, Fizazi K, Herrmann K, Rahbar K . Lutetium-177-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer. N Engl J Med. 2021; 385(12):1091-1103. PMC: 8446332. DOI: 10.1056/NEJMoa2107322. View

Bouchelouche K, Turkbey B, Choyke P . PSMA PET and Radionuclide Therapy in Prostate Cancer. Semin Nucl Med. 2016; 46(6):522-535. PMC: 5123597. DOI: 10.1053/j.semnuclmed.2016.07.006. View

Ristau B, OKeefe D, Bacich D . The prostate-specific membrane antigen: lessons and current clinical implications from 20 years of research. Urol Oncol. 2013; 32(3):272-9. PMC: 3972351. DOI: 10.1016/j.urolonc.2013.09.003. View

Virgolini I, Decristoforo C, Haug A, Fanti S, Uprimny C . Current status of theranostics in prostate cancer. Eur J Nucl Med Mol Imaging. 2017; 45(3):471-495. PMC: 5787224. DOI: 10.1007/s00259-017-3882-2. View

Kratochwil C, Giesel F, Stefanova M, Benesova M, Bronzel M, Afshar-Oromieh A . PSMA-Targeted Radionuclide Therapy of Metastatic Castration-Resistant Prostate Cancer with 177Lu-Labeled PSMA-617. J Nucl Med. 2016; 57(8):1170-6. DOI: 10.2967/jnumed.115.171397. View

Alsadi R, Bouhali O, Dewji S, Djekidel M . 177Lu-PSMA Therapy for Metastatic Castration-Resistant Prostate Cancer: A Mini-Review of State-of-the-Art. Oncologist. 2022; 27(12):e957-e966. PMC: 10249427. DOI: 10.1093/oncolo/oyac216. View

Rahbar K, Ahmadzadehfar H, Kratochwil C, Haberkorn U, Schafers M, Essler M . German Multicenter Study Investigating 177Lu-PSMA-617 Radioligand Therapy in Advanced Prostate Cancer Patients. J Nucl Med. 2016; 58(1):85-90. DOI: 10.2967/jnumed.116.183194. View

10.

OKeefe D, Bacich D, Heston W . Comparative analysis of prostate-specific membrane antigen (PSMA) versus a prostate-specific membrane antigen-like gene. Prostate. 2004; 58(2):200-10. DOI: 10.1002/pros.10319. View

11.

Silver D, Pellicer I, Fair W, Heston W, Cordon-Cardo C . Prostate-specific membrane antigen expression in normal and malignant human tissues. Clin Cancer Res. 1997; 3(1):81-5. View

12.

Ling S, de Blois E, Hooijman E, van der Veldt A, Brabander T . Advances in Lu-PSMA and Ac-PSMA Radionuclide Therapy for Metastatic Castration-Resistant Prostate Cancer. Pharmaceutics. 2022; 14(10). PMC: 9607057. DOI: 10.3390/pharmaceutics14102166. View

13.

Kabasakal L, Abuqbeitah M, Aygun A, Yeyin N, Ocak M, Demirci E . Pre-therapeutic dosimetry of normal organs and tissues of (177)Lu-PSMA-617 prostate-specific membrane antigen (PSMA) inhibitor in patients with castration-resistant prostate cancer. Eur J Nucl Med Mol Imaging. 2015; 42(13):1976-83. DOI: 10.1007/s00259-015-3125-3. View

14.

Kratochwil C, Giesel F, Leotta K, Eder M, Hoppe-Tich T, Youssoufian H . PMPA for nephroprotection in PSMA-targeted radionuclide therapy of prostate cancer. J Nucl Med. 2015; 56(2):293-8. DOI: 10.2967/jnumed.114.147181. View

15.

Zechmann C, Afshar-Oromieh A, Armor T, Stubbs J, Mier W, Hadaschik B . Radiation dosimetry and first therapy results with a (124)I/ (131)I-labeled small molecule (MIP-1095) targeting PSMA for prostate cancer therapy. Eur J Nucl Med Mol Imaging. 2014; 41(7):1280-92. PMC: 4052014. DOI: 10.1007/s00259-014-2713-y. View

16.

Chatalic K, Heskamp S, Konijnenberg M, Molkenboer-Kuenen J, Franssen G, Clahsen-van Groningen M . Towards Personalized Treatment of Prostate Cancer: PSMA I&T, a Promising Prostate-Specific Membrane Antigen-Targeted Theranostic Agent. Theranostics. 2016; 6(6):849-61. PMC: 4860893. DOI: 10.7150/thno.14744. View

17.

Maurer T, Eiber M, Schwaiger M, Gschwend J . Current use of PSMA-PET in prostate cancer management. Nat Rev Urol. 2016; 13(4):226-35. DOI: 10.1038/nrurol.2016.26. View

18.

Yordanova A, Becker A, Eppard E, Kurpig S, Fisang C, Feldmann G . The impact of repeated cycles of radioligand therapy using [Lu]Lu-PSMA-617 on renal function in patients with hormone refractory metastatic prostate cancer. Eur J Nucl Med Mol Imaging. 2017; 44(9):1473-1479. DOI: 10.1007/s00259-017-3681-9. View

19.

Delker A, Fendler W, Kratochwil C, Brunegraf A, Gosewisch A, Gildehaus F . Dosimetry for (177)Lu-DKFZ-PSMA-617: a new radiopharmaceutical for the treatment of metastatic prostate cancer. Eur J Nucl Med Mol Imaging. 2015; 43(1):42-51. DOI: 10.1007/s00259-015-3174-7. View

20.

Baum R, Kulkarni H, Schuchardt C, Singh A, Wirtz M, Wiessalla S . 177Lu-Labeled Prostate-Specific Membrane Antigen Radioligand Therapy of Metastatic Castration-Resistant Prostate Cancer: Safety and Efficacy. J Nucl Med. 2016; 57(7):1006-13. DOI: 10.2967/jnumed.115.168443. View